Jonathan Faison

Most friends know my story, but new followers probably don't - short version: -Am a Wall Street Nobody, started investing in 2008 with no one to teach me & made every mistake in the book (& then some, very lucky to have survived them) -Writing on SA been a hobby for long time (comments were brutal, forced me to keep improving & showed just how little I truly know about this sector) -After university went to Peru (figured have some fun before getting a "real job", 6 months turned into 15 years there 😂 -Committed career suicide by quitting a lucrative finance job to instead teach English at university. One night out at a club with friends, met a salsa dancer then turned into a 10yr relationship/7yr marriage -Along the way, used clinical-stage biotech wins to start a couple successful businesses (restaurant & fashion), also bought a condo to diversify. Biggest binary loss was ironically not biotech but instead a divorce Xmas 2021 (such is life sometimes, thankful for what I got) -Started from square one again as a biotech hobo, spending about 3 months in each country for 2+ years now. Life often turns out differently than we expect, but it's still pretty grand and good reminder that God always has a plan for each of us 🤙 Normally don't deviate into the personal, but hope it gives perspective for anything I post in the future Cheers my friends 🙂 – at Limón, Costa Rica

Really great call - my favorite theme was how to benefit from our rough patches & countering a negative mindset 👍 Thanks to all who kept the conversation flowing, including @WassimLaroussi3 @lfholt @Sanctuary_Bio @JoseRestonVA and others not on X Have a great weekend all 🤝

$INO - great call @AaronRosenblum5 👏 Also, more evidence of a rare-disease friendly FDA is good for the sector $XBI $QURE $CAPR

Coffee at the Close call in 15 minutes $XBI

Fwiw, $IOVA back on my DD list (expect the weakness to continue for some time though) Perhaps one man's trash will be another's treasure at the right price TILVANCE-301 frontline melanoma trial has March 2028 primary completion date (ORR interim prior) IL-12 tethered TIL unlocks cold tumors, next-gen IL-2 reduces AE burden from conditioning Expansion indications of endometrial cancer & sarcoma should've made good progress by then 110 active ATC sites by year-end (infrastructure = significant strategic value to larger players vs having to scale up from scratch, can always improve the tech along the way) Ideal scenario= pendulum swings to being out of favor again, overreaction lasts well into 2027 before reverting Whether this name or others on radar, Goal= let optimal setups come to me (not chasing)

$IBB quietly breaking out 🧐 Commercial-stage bio is the place to be (hat tip to Premie)

Deserves a sticky note on my laptop for biotech "gut punches" $XBI

You are invincible if nothing outside the will can disconcert you. - Epictetus

I've been blocked by a lot of people for my devil's advocate posts, is what it is. Occasionally just a misunderstanding - will continue to focus on adding value where we can, the rest takes care of itself.

$IOVA - greatly respect longs like @kainvests that instead of stubbornly clinging to their original thesis, are quick to admit where it's been negatively impacted 1) "Durability has substantially regressed" - clear that low dose lymphodepletion adversely affecting DoR 2) Mgmt misled investors going into the update, plain & simple (coming from someone whose weakness is also being slow to admit where he's wrong... and pays dearly for it - I could learn a thing or two!)

$OMER shaking off EU rejection, curling up nicely here 👍

$IOVA (NP) One last point- if the data were strong & this were truly a "sell the news" reaction, I'd be in or at least seriously considering (Playbook) However, there's very low probability of accelerated approval as it stands (in addition to concerns raised by relying on subset analysis) Scenario where they get a lung approval which leads to accelerating revenue growth that paves the way for sarcoma & endometrial cancer = highly attractive to my eyes OTOH, one where lung's in limbo and we have to wait multiple years for approvable data sets in other indications = type of situations I try to avoid My two cents... GLTA (& be careful, a lot of unfounded cheerleading out there today)